Maze has reached a pivotal moment in our journey. On the heels of a successful IPO and with two ongoing clinical-stage programs – MZE829 for ...

Maze Therapeutics, Inc. (NASDAQ:MAZE – Free Report) – Research analysts at Leerink Partnrs cut their Q1 2025 earnings per share (EPS) estimates for shares of Maze Therapeutics in a research ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

In a report released today, Tyler Van Buren from TD Cowen maintained a Buy rating on Maze Therapeutics, Inc. (MAZE – Research Report). The ...